Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

An economic analysis of Chemo Mouthpiece® versus supportive care for the reduction of oral mucositis incidence in patients receiving chemotherapy.

PMID: 41757395 ·

Richard Zuniga, Aidan Dineen, Rosemarie Velasquez, Donghyun D Lee, Anthony Zara, Bonni Tattoli, Megan Bourque, Frank Jacobucci

JournalJournal of comparative effectiveness research
Year
PMID41757395

Abstract

Aim: Oral mucositis (OM) is a common, burdensome complication of chemotherapy (CT), associated with pain, weight loss and increased infection risk. OM can result in CT dose reductions or delay subsequent cycles, compromising treatment efficacy. Current guidelines recommend oral cryotherapy with basic multiagent oral care for prevention of CT-induced OM. Chemo Mouthpiece® (CMP) is a cryotherapy medical device with FDA 510(k) marketing clearance. A randomized controlled trial demonstrated that CMP

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.

↑